Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28639420,AUC,"The median AUC of enalaprilat in the control group was not significantly different from any of the other five groups (297 ng/ml x h in the control group versus 310, 282, 294, 344 and 306 ng/ml x h in groups 2-6, respectively).",The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639420/),[ng] / [h·ml],297,180,DB00584,Enalapril
,28639420,AUC,"The median AUC of enalaprilat in the control group was not significantly different from any of the other five groups (297 ng/ml x h in the control group versus 310, 282, 294, 344 and 306 ng/ml x h in groups 2-6, respectively).",The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639420/),[ng] / [h·ml],310,181,DB00584,Enalapril
,28639420,AUC,"The median AUC of enalaprilat in the control group was not significantly different from any of the other five groups (297 ng/ml x h in the control group versus 310, 282, 294, 344 and 306 ng/ml x h in groups 2-6, respectively).",The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639420/),[ng] / [h·ml],28,182,DB00584,Enalapril
,28639420,AUC,"The median AUC of enalaprilat in the control group was not significantly different from any of the other five groups (297 ng/ml x h in the control group versus 310, 282, 294, 344 and 306 ng/ml x h in groups 2-6, respectively).",The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639420/),[ng] / [h·ml],2,183,DB00584,Enalapril
,28639420,AUC,"The median AUC of enalaprilat in the control group was not significantly different from any of the other five groups (297 ng/ml x h in the control group versus 310, 282, 294, 344 and 306 ng/ml x h in groups 2-6, respectively).",The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639420/),[ng] / [h·ml],294,184,DB00584,Enalapril
,28639420,AUC,"The median AUC of enalaprilat in the control group was not significantly different from any of the other five groups (297 ng/ml x h in the control group versus 310, 282, 294, 344 and 306 ng/ml x h in groups 2-6, respectively).",The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639420/),[ng] / [h·ml],344,185,DB00584,Enalapril
,28639420,AUC,"The median AUC of enalaprilat in the control group was not significantly different from any of the other five groups (297 ng/ml x h in the control group versus 310, 282, 294, 344 and 306 ng/ml x h in groups 2-6, respectively).",The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639420/),[ng] / [h·ml],306,186,DB00584,Enalapril
,28639420,terminal half-life,"The terminal half-life of enalaprilat was significantly longer in group 6 compared with the control group (26.7 hr versus 12.7 hr, respectively).",The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639420/),h,26.7,187,DB00584,Enalapril
,28639420,terminal half-life,"The terminal half-life of enalaprilat was significantly longer in group 6 compared with the control group (26.7 hr versus 12.7 hr, respectively).",The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639420/),h,12.7,188,DB00584,Enalapril
,24127029,maximum plasma concentration,"In pigeons, after application of 2.5 mg/kg enalapril, the maximum plasma concentration was found in the first sample taken (388.2 ± 174.1 mg/kg).",[Examinations on the pharmacokinetics and compatibility of enalapril in racing pigeons]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127029/),[mg] / [kg],388.2,4576,DB00584,Enalapril
,24127029,maximum concentration,The application of 1.25 mg/kg resulted in a maximum concentration of 116.1 ± 70.2 ng/ml after 30 minutes in pigeons.,[Examinations on the pharmacokinetics and compatibility of enalapril in racing pigeons]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127029/),[ng] / [ml],116.1,4577,DB00584,Enalapril
,24127029,maximum value,"In the Amazon birds, the maximum value was found after 1 hour (first sampling) of 43.3 ±6.0 ng/ml.",[Examinations on the pharmacokinetics and compatibility of enalapril in racing pigeons]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127029/),[ng] / [ml],43.3,4578,DB00584,Enalapril
,24127029,terminal half-life,The terminal half-life was 2.68 hours for pigeons and 2.36 hours for Amazons.,[Examinations on the pharmacokinetics and compatibility of enalapril in racing pigeons]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127029/),h,2.68,4579,DB00584,Enalapril
,24127029,terminal half-life,The terminal half-life was 2.68 hours for pigeons and 2.36 hours for Amazons.,[Examinations on the pharmacokinetics and compatibility of enalapril in racing pigeons]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127029/),h,2.36,4580,DB00584,Enalapril
,24788577,flow rate,Under gradient conditions and a flow rate of 0.4 mL/min the column effluent was monitored by tandem mass spectrometry with electrospray ionization.,"Simultaneous quantitative and qualitative analysis of aliskiren, enalapril and its active metabolite enalaprilat in undiluted human urine utilizing LC-ESI-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24788577/),[ml] / [min],0.4,6356,DB00584,Enalapril
,12177688,time to reach the maximum plasma concentration (T(max)),The time to reach the maximum plasma concentration (T(max)) is 2.0 h for imidapril and 9.3 h for imidaprilat.,"Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,2.0,8600,DB00584,Enalapril
,12177688,time to reach the maximum plasma concentration (T(max)),The time to reach the maximum plasma concentration (T(max)) is 2.0 h for imidapril and 9.3 h for imidaprilat.,"Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,9.3,8601,DB00584,Enalapril
,12177688,elimination half-lives (t(1/2)),"The elimination half-lives (t(1/2)) of imidapril and imidaprilat is 1.7 and 14.8 h, respectively.","Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,1.7,8602,DB00584,Enalapril
,12177688,elimination half-lives (t(1/2)),"The elimination half-lives (t(1/2)) of imidapril and imidaprilat is 1.7 and 14.8 h, respectively.","Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,14.8,8603,DB00584,Enalapril
,6100610,serum half-life,"Peak serum EA concentrations occur 4 h after an oral dose; its serum half-life is approximately 35 h, and steady state is achieved by the fourth day of treatment.",The clinical pharmacology of enalapril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6100610/),h,35,22888,DB00584,Enalapril
,32651896,Cmax,Pharmacokinetics studies indicated a significantly lower Cmax of EP (125.22 ± 6.32) and SG (75.63 ± 3.85) and higher mean Tmax values (9.4 h for EP and 10.73 h for SG) from OLF in comparison with reference brands of EP (257.54 ± 8.23 ng/mL) and SG (393.66 ± 2.97 ng/mL).,"Lipospheres for Simultaneous Controlled Release and Improved Pharmacokinetic Profiles of Saxagliptin-Enalapril: Formulation, Optimization, and Comparative In Vitro-In Vivo Evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32651896/),,125.22,23789,DB00584,Enalapril
,32651896,Cmax,Pharmacokinetics studies indicated a significantly lower Cmax of EP (125.22 ± 6.32) and SG (75.63 ± 3.85) and higher mean Tmax values (9.4 h for EP and 10.73 h for SG) from OLF in comparison with reference brands of EP (257.54 ± 8.23 ng/mL) and SG (393.66 ± 2.97 ng/mL).,"Lipospheres for Simultaneous Controlled Release and Improved Pharmacokinetic Profiles of Saxagliptin-Enalapril: Formulation, Optimization, and Comparative In Vitro-In Vivo Evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32651896/),,75.63,23790,DB00584,Enalapril
,32651896,Tmax,Pharmacokinetics studies indicated a significantly lower Cmax of EP (125.22 ± 6.32) and SG (75.63 ± 3.85) and higher mean Tmax values (9.4 h for EP and 10.73 h for SG) from OLF in comparison with reference brands of EP (257.54 ± 8.23 ng/mL) and SG (393.66 ± 2.97 ng/mL).,"Lipospheres for Simultaneous Controlled Release and Improved Pharmacokinetic Profiles of Saxagliptin-Enalapril: Formulation, Optimization, and Comparative In Vitro-In Vivo Evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32651896/),h,9.4,23791,DB00584,Enalapril
,32651896,Tmax,Pharmacokinetics studies indicated a significantly lower Cmax of EP (125.22 ± 6.32) and SG (75.63 ± 3.85) and higher mean Tmax values (9.4 h for EP and 10.73 h for SG) from OLF in comparison with reference brands of EP (257.54 ± 8.23 ng/mL) and SG (393.66 ± 2.97 ng/mL).,"Lipospheres for Simultaneous Controlled Release and Improved Pharmacokinetic Profiles of Saxagliptin-Enalapril: Formulation, Optimization, and Comparative In Vitro-In Vivo Evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32651896/),h,10.73,23792,DB00584,Enalapril
,32651896,Tmax,Pharmacokinetics studies indicated a significantly lower Cmax of EP (125.22 ± 6.32) and SG (75.63 ± 3.85) and higher mean Tmax values (9.4 h for EP and 10.73 h for SG) from OLF in comparison with reference brands of EP (257.54 ± 8.23 ng/mL) and SG (393.66 ± 2.97 ng/mL).,"Lipospheres for Simultaneous Controlled Release and Improved Pharmacokinetic Profiles of Saxagliptin-Enalapril: Formulation, Optimization, and Comparative In Vitro-In Vivo Evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32651896/),[ng] / [ml],257.54,23793,DB00584,Enalapril
,32651896,Tmax,Pharmacokinetics studies indicated a significantly lower Cmax of EP (125.22 ± 6.32) and SG (75.63 ± 3.85) and higher mean Tmax values (9.4 h for EP and 10.73 h for SG) from OLF in comparison with reference brands of EP (257.54 ± 8.23 ng/mL) and SG (393.66 ± 2.97 ng/mL).,"Lipospheres for Simultaneous Controlled Release and Improved Pharmacokinetic Profiles of Saxagliptin-Enalapril: Formulation, Optimization, and Comparative In Vitro-In Vivo Evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32651896/),[ng] / [ml],393.66,23794,DB00584,Enalapril
,3011046,F,There was no difference in F between young (0.62 +/- 0.16) and elderly subjects (0.61 +/- 0.15).,Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3011046/),,0.62,24969,DB00584,Enalapril
,3011046,F,There was no difference in F between young (0.62 +/- 0.16) and elderly subjects (0.61 +/- 0.15).,Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3011046/),,0.61,24970,DB00584,Enalapril
,2527539,Di,6. Dialysis clearance was approximately 2 l h-1 for cilazapril and for cilazaprilat.,Pharmacokinetics of cilazapril in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2527539/),[l] / [h],2,28907,DB00584,Enalapril
,3032562,absorption,"Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%.",Pharmacokinetics of enalapril in congestive heart failure. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032562/),%,69,29093,DB00584,Enalapril
,3032562,absorption,"Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%.",Pharmacokinetics of enalapril in congestive heart failure. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032562/),%,55,29094,DB00584,Enalapril
,3032562,bioavailability,"Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%.",Pharmacokinetics of enalapril in congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032562/),%,38,29095,DB00584,Enalapril
,3032562,first,"Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%.",Pharmacokinetics of enalapril in congestive heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032562/),%,10,29096,DB00584,Enalapril
,21953651,flow rate,"After solid-phase extraction, chromatography was performed on a Luna(®) RP-C(18) (2) column with methanol-water-formic acid (65:35:1, v/v/v) as mobile phase and a flow rate of 0.4 mL/min.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),[ml] / [min],0.4,33669,DB00584,Enalapril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,377.3,33670,DB00584,Enalapril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,234.2,33671,DB00584,Enalapril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,349.3,33672,DB00584,Enalapril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,206.1,33673,DB00584,Enalapril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,425.3,33674,DB00584,Enalapril
,8205376,terminal elimination half-life,"The mean terminal elimination half-life following a single administration of 10 mg enalapril, was 27 hours.","Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205376/),h,27,34166,DB00584,Enalapril
,25646154,AUC0- ∞,"Mean (SD) AUC0- ∞ for DOX and doxorubicinol with enalapril exposure was 1185.56 (44.64) hr*ng/ml and 1040 (80.6) hr*ng/ml, respectively.",Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25646154/),[h·ng] / [ml],1185.56,41595,DB00584,Enalapril
,25646154,AUC0- ∞,"Mean (SD) AUC0- ∞ for DOX and doxorubicinol with enalapril exposure was 1185.56 (44.64) hr*ng/ml and 1040 (80.6) hr*ng/ml, respectively.",Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25646154/),[h·ng] / [ml],1040,41596,DB00584,Enalapril
,25646154,AUC0- ∞,"AUC0- ∞ for DOX and doxobubicinol without enalapril was 1167.73 (45.26) hr*ng/ml and 1056.32 (92.03) hr*ng/ml, respectively.",Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25646154/),[h·ng] / [ml],1167.73,41597,DB00584,Enalapril
,25646154,AUC0- ∞,"AUC0- ∞ for DOX and doxobubicinol without enalapril was 1167.73 (45.26) hr*ng/ml and 1056.32 (92.03) hr*ng/ml, respectively.",Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25646154/),[h·ng] / [ml],1056.32,41598,DB00584,Enalapril
,17523052,IC(50),Enalaprilat inhibited the hydrolysis of BIO1211 in a concentration-dependent manner with IC(50) values of 2 nM in human and sheep plasma and 10 nM in rat plasma.,Effect of enalapril on the in vitro and in vivo peptidyl cleavage of a potent VLA-4 antagonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523052/),nM,2,42375,DB00584,Enalapril
,17523052,IC(50),Enalaprilat inhibited the hydrolysis of BIO1211 in a concentration-dependent manner with IC(50) values of 2 nM in human and sheep plasma and 10 nM in rat plasma.,Effect of enalapril on the in vitro and in vivo peptidyl cleavage of a potent VLA-4 antagonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523052/),nM,10,42376,DB00584,Enalapril
,2550637,AUC0-48 h,Co-administration of hydralazine significantly increased the area under the plasma concentration time curve (AUC) of lisinopril (AUC0-48 h 766.8 +/- 66.3 ng.h/ml (lisinopril) vs 1022.3 +/- 115.3 ng.h/ml (lisinopril + hydralazine)).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],766.8,48253,DB00584,Enalapril
,2550637,AUC0-48 h,Co-administration of hydralazine significantly increased the area under the plasma concentration time curve (AUC) of lisinopril (AUC0-48 h 766.8 +/- 66.3 ng.h/ml (lisinopril) vs 1022.3 +/- 115.3 ng.h/ml (lisinopril + hydralazine)).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],1022.3,48254,DB00584,Enalapril
,2550637,AUC,This did not occur with enalaprilat (AUC 710.1 +/- 51.2 ng.h/ml (enalapril) vs 681.9 +/- 44.9 ng.h/ml (enalapril + hydralazine); mean +/- SEM).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],710.1,48255,DB00584,Enalapril
,2550637,AUC,This did not occur with enalaprilat (AUC 710.1 +/- 51.2 ng.h/ml (enalapril) vs 681.9 +/- 44.9 ng.h/ml (enalapril + hydralazine); mean +/- SEM).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],681.9,48256,DB00584,Enalapril
,6124377,Absorption,Absorption was estimated to be 34% in the rat and 61% in the dog.,The physiological disposition and metabolism of enalapril maleate in laboratory animals. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124377/),%,34,48657,DB00584,Enalapril
,6124377,Absorption,Absorption was estimated to be 34% in the rat and 61% in the dog.,The physiological disposition and metabolism of enalapril maleate in laboratory animals. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124377/),%,61,48658,DB00584,Enalapril
,6091806,effective half-life for accumulation,An average effective half-life for accumulation of approximately 11h was calculated from urine data.,Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091806/),h,11,49566,DB00584,Enalapril
,6091806,accumulation ratio,An accumulation ratio of 1.3 for enalaprilat was calculated from the predicted steady-state urinary recovery and observed urinary recovery for dose one.,Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091806/),,1.3,49567,DB00584,Enalapril
,2550636,maximum serum concentration (Cmax),"The maximum serum concentration (Cmax) of lisinopril and time to reach maximum concentration (Tmax) were 64 +/- 16 ng/ml and 7.5 +/- 1.5 h, respectively.","Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ng] / [ml],64,52064,DB00584,Enalapril
,2550636,time to reach maximum concentration (Tmax),"The maximum serum concentration (Cmax) of lisinopril and time to reach maximum concentration (Tmax) were 64 +/- 16 ng/ml and 7.5 +/- 1.5 h, respectively.","Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),h,7.5,52065,DB00584,Enalapril
,2550636,area under the serum curve (AUC),The area under the serum curve (AUC) was 916 +/- 239 h.,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),h,916,52066,DB00584,Enalapril
,2550636,Cmax,The Cmax of enalaprilat (89 +/- 34 ng/ml) was greater than that of lisinopril whilst Tmax was shorter (4.3 +/- 1.7 h) and AUC smaller (718 +/- 17 h.ng/ml) (P less than 0.01).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ng] / [ml],89,52067,DB00584,Enalapril
,2550636,Tmax,The Cmax of enalaprilat (89 +/- 34 ng/ml) was greater than that of lisinopril whilst Tmax was shorter (4.3 +/- 1.7 h) and AUC smaller (718 +/- 17 h.ng/ml) (P less than 0.01).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),h,4.3,52068,DB00584,Enalapril
,2550636,AUC,The Cmax of enalaprilat (89 +/- 34 ng/ml) was greater than that of lisinopril whilst Tmax was shorter (4.3 +/- 1.7 h) and AUC smaller (718 +/- 17 h.ng/ml) (P less than 0.01).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[h·ng] / [ml],718,52069,DB00584,Enalapril
,2550636,Renal clearance of drug,Renal clearance of drug 48 h post-dosing showed that enalaprilat (164 +/- 38 ml/min) was cleared from plasma significantly more rapidly than lisinopril (82 +/- 16 ml/min) (P less than 0.001).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ml] / [min],164,52070,DB00584,Enalapril
,2550636,Renal clearance of drug,Renal clearance of drug 48 h post-dosing showed that enalaprilat (164 +/- 38 ml/min) was cleared from plasma significantly more rapidly than lisinopril (82 +/- 16 ml/min) (P less than 0.001).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ml] / [min],82,52071,DB00584,Enalapril
,11881130,trough serum concentration,The daily dose of enalapril was 10 (2.5-20) mg and the trough serum concentration of enalaprilat was 31.8 (<2.5-584.7)ng/ml.,High serum enalaprilat in chronic renal failure. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881130/),[ng] / [ml],31.8,57913,DB00584,Enalapril
,11881130,clearance,"The median clearance of enalaprilat was 28 (16-68) ml/minute and correlated linearly with GFR (r=0.86, p=0.003).",High serum enalaprilat in chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881130/),[ml] / [min],28,57914,DB00584,Enalapril
lower,7512472,trough: peak ratios,Other ACE inhibitors had trough: peak ratios lower than 50%.,Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7512472/),,50,61290,DB00584,Enalapril
,6100875,accumulation half-life,Comparison between the observed and predicted steady-state urinary recoveries of enalaprilat yields an effective accumulation half-life of approximately 11 h.,Kinetic and metabolic aspects of enalapril action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6100875/),h,11,63271,DB00584,Enalapril
,2849471,IC50,"Calculated IC50 was 47 ng lisinopril ml-1. from pooled data, with individual patients IC50 ranging from 20 to 70 ng lisinopril ml-1.",Lisinopril pharmacokinetics in chronic renal failure. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849471/),[lisinopril·ng] / [ml],47,69673,DB00584,Enalapril
,2849471,IC50,"Calculated IC50 was 47 ng lisinopril ml-1. from pooled data, with individual patients IC50 ranging from 20 to 70 ng lisinopril ml-1.",Lisinopril pharmacokinetics in chronic renal failure. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849471/),[lisinopril·ng] / [ml],20 to 70,69674,DB00584,Enalapril
,1647954,time to peak serum concentration (tmax),"The time to peak serum concentration (tmax) of enalapril was increased after administration at 20.00 h compared to 08.00 h (2.4 h versus 1.3 h), whereas other kinetic parameters were not significantly altered.",Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1647954/),h,2.4,71410,DB00584,Enalapril
,1647954,time to peak serum concentration (tmax),"The time to peak serum concentration (tmax) of enalapril was increased after administration at 20.00 h compared to 08.00 h (2.4 h versus 1.3 h), whereas other kinetic parameters were not significantly altered.",Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1647954/),h,1.3,71411,DB00584,Enalapril
,15797799,flow rate,"The HPLC was carried out on a Lichrosphere 60RP-select B, C18, 5 microm (125 mm x 4.0 mm i.d.) column at flow rate of 1.0 ml/min.",High-performance liquid chromatographic determination of enalapril in human plasma by enzyme kinetic analytical method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15797799/),[ml] / [min],1.0,74547,DB00584,Enalapril
,15797799,analysis time per injection,The analysis time per injection was within 6.5 min.,High-performance liquid chromatographic determination of enalapril in human plasma by enzyme kinetic analytical method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15797799/),min,6.5,74548,DB00584,Enalapril
,16181761,recoveries,The recoveries of ramipril and ramiprilat from serum were in the range of 81.0-98.2%.,High-performance liquid chromatography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: application to a pharmacokinetic study in the Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16181761/),%,81.0-98.2,76277,DB00584,Enalapril
,22418829,Terminal t(1/2),"Terminal t(1/2), best characterized following a dose of 1,000 mg, was 41.6 h and t(max) 4-5 h post-dose.",Entry-into-humans study with a new direct renin inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418829/),h,41.6,76487,DB00584,Enalapril
,22418829,t(max),"Terminal t(1/2), best characterized following a dose of 1,000 mg, was 41.6 h and t(max) 4-5 h post-dose.",Entry-into-humans study with a new direct renin inhibitor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418829/),h,4-5,76488,DB00584,Enalapril
,9269955,concentrations inducing half-maximal effects,"Maximal effects, concentrations inducing half-maximal effects, and Hill coefficients were -99 +/- 2%, 3.9 +/- 1.9 ng/ml, and 2.4 +/- 0.7 for PCEA inhibition, -15 +/- 8 mm Hg, 11.8 +/- 9.2 ng/ml, and 2.6 +/- 1.3 for PCWP decrease, and 36 +/- 19 ml/min, 13.8 +/- 7.6 ng/ml, and 3.3 +/- 1.0 for BBF increase.",Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269955/),[ng] / [ml],11.8,80575,DB00584,Enalapril
,9269955,concentrations inducing half-maximal effects,"Maximal effects, concentrations inducing half-maximal effects, and Hill coefficients were -99 +/- 2%, 3.9 +/- 1.9 ng/ml, and 2.4 +/- 0.7 for PCEA inhibition, -15 +/- 8 mm Hg, 11.8 +/- 9.2 ng/ml, and 2.6 +/- 1.3 for PCWP decrease, and 36 +/- 19 ml/min, 13.8 +/- 7.6 ng/ml, and 3.3 +/- 1.0 for BBF increase.",Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269955/),[ng] / [ml],13.8,80576,DB00584,Enalapril
,9269955,Hill coefficients,"Maximal effects, concentrations inducing half-maximal effects, and Hill coefficients were -99 +/- 2%, 3.9 +/- 1.9 ng/ml, and 2.4 +/- 0.7 for PCEA inhibition, -15 +/- 8 mm Hg, 11.8 +/- 9.2 ng/ml, and 2.6 +/- 1.3 for PCWP decrease, and 36 +/- 19 ml/min, 13.8 +/- 7.6 ng/ml, and 3.3 +/- 1.0 for BBF increase.",Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269955/),,2.4,80577,DB00584,Enalapril
,9269955,Hill coefficients,"Maximal effects, concentrations inducing half-maximal effects, and Hill coefficients were -99 +/- 2%, 3.9 +/- 1.9 ng/ml, and 2.4 +/- 0.7 for PCEA inhibition, -15 +/- 8 mm Hg, 11.8 +/- 9.2 ng/ml, and 2.6 +/- 1.3 for PCWP decrease, and 36 +/- 19 ml/min, 13.8 +/- 7.6 ng/ml, and 3.3 +/- 1.0 for BBF increase.",Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269955/),[ng] / [ml],13.8,80578,DB00584,Enalapril
,9269955,Hill coefficients,"Maximal effects, concentrations inducing half-maximal effects, and Hill coefficients were -99 +/- 2%, 3.9 +/- 1.9 ng/ml, and 2.4 +/- 0.7 for PCEA inhibition, -15 +/- 8 mm Hg, 11.8 +/- 9.2 ng/ml, and 2.6 +/- 1.3 for PCWP decrease, and 36 +/- 19 ml/min, 13.8 +/- 7.6 ng/ml, and 3.3 +/- 1.0 for BBF increase.",Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269955/),,3.3,80579,DB00584,Enalapril
,8276049,bioavailability,"In contrast, the bioavailability of spiraprilat, the metabolite responsible for the pharmacological action of spirapril, was significantly reduced in patients (AUC 820 micrograms.",Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276049/),μg,820,82032,DB00584,Enalapril
,8276049,AUC,"In contrast, the bioavailability of spiraprilat, the metabolite responsible for the pharmacological action of spirapril, was significantly reduced in patients (AUC 820 micrograms.",Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276049/),μg,820,82033,DB00584,Enalapril
,8276049,rate constant,"Compared to healthy subjects, cirrhotic patients had a reduced rate constant of spiraprilat formation (1.10 h-1 in patients vs. 2.00 h-1 in control subjects) while the elimination half-life of spiraprilat was not different.",Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276049/),1/[h],1.10,82034,DB00584,Enalapril
,8276049,rate constant,"Compared to healthy subjects, cirrhotic patients had a reduced rate constant of spiraprilat formation (1.10 h-1 in patients vs. 2.00 h-1 in control subjects) while the elimination half-life of spiraprilat was not different.",Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276049/),1/[h],2.00,82035,DB00584,Enalapril
,11523062,T(max),"Suspension T(max) was slightly shorter (0.5 h) than that for tablet, but this difference is not clinically significant.",Pharmacokinetic assessment of an oral enalapril suspension for use in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523062/),h,0.5,85788,DB00584,Enalapril
,16912985,run-times,"Furthermore, the short run-times (2 min) involved are compatible with the requirements of large-scale clinical studies.",Determination of zaltoprofen in human plasma by liquid chromatography with electrospray tandem mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912985/),min,2,86842,DB00584,Enalapril
,16912985,m/z,Ion acquisition was performed in multiple reaction monitoring (MRM) mode by monitoring the transitions m/z 299.3 > 225.0 for zaltoprofen and m/z 377.4 > 234.2 for the IS enalapril.,Determination of zaltoprofen in human plasma by liquid chromatography with electrospray tandem mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912985/),,377.4,86843,DB00584,Enalapril
,16912985,m/z,Ion acquisition was performed in multiple reaction monitoring (MRM) mode by monitoring the transitions m/z 299.3 > 225.0 for zaltoprofen and m/z 377.4 > 234.2 for the IS enalapril.,Determination of zaltoprofen in human plasma by liquid chromatography with electrospray tandem mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912985/),,234.2,86844,DB00584,Enalapril
,16912985,limit of detection (LOD),The limit of detection (LOD) was 0.01 microg/mL and the lower limit of quantitation (LLOQ) was 0.05 microg/mL.,Determination of zaltoprofen in human plasma by liquid chromatography with electrospray tandem mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912985/),[μg] / [ml],0.01,86845,DB00584,Enalapril
,16912985,run-time,"The devised method was linear over the studied range (0.05-20 microg/mL), with r2 > 0.99 and a run-time of 2 min.",Determination of zaltoprofen in human plasma by liquid chromatography with electrospray tandem mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912985/),min,2,86846,DB00584,Enalapril
,22263871,heart rate,He was found to be bradycardic with a heart rate of 42/min.,"Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),1/[min],42,90698,DB00584,Enalapril
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],14,90699,DB00584,Enalapril
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],7,90700,DB00584,Enalapril
,8261712,elimination half-life,"Elimination thereafter is biphasic, with an initial phase which reflects renal filtration (elimination half-life 2 to 6 hours) and a subsequent prolonged phase (elimination half-life 36 hours), the latter representing equilibration of drug from tissue distribution sites.",Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261712/),h,2 to 6,91440,DB00584,Enalapril
,8261712,elimination half-life,"Elimination thereafter is biphasic, with an initial phase which reflects renal filtration (elimination half-life 2 to 6 hours) and a subsequent prolonged phase (elimination half-life 36 hours), the latter representing equilibration of drug from tissue distribution sites.",Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261712/),h,36,91441,DB00584,Enalapril
,3014110,area under the serum concentration-time curve (AUC0-120h,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[h·ng] / [ml],1231,97037,DB00584,Enalapril
,3014110,area under the serum concentration-time curve (AUC0-120h,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[h·ng] / [ml],1029,97038,DB00584,Enalapril
,3014110,peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[ng] / [ml],86,97039,DB00584,Enalapril
,3014110,peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[ng] / [ml],69,97040,DB00584,Enalapril
,3014110,time to peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),h,6.2,97041,DB00584,Enalapril
,3014110,time to peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),h,6.8,97042,DB00584,Enalapril
,3014110,urinary excretion,Five-day urinary excretion of lisinopril was not altered by food (5.3 +/- 3.0 versus 5.1 +/- 2.0 mg).,"Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),mg,5.3,97043,DB00584,Enalapril
,3014110,urinary excretion,Five-day urinary excretion of lisinopril was not altered by food (5.3 +/- 3.0 versus 5.1 +/- 2.0 mg).,"Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),mg,5.1,97044,DB00584,Enalapril
,3014110,bioavailability,"Based on the urinary data, the mean +/- SD bioavailability of lisinopril was not different following fasting or fed regimens (27 +/- 15 versus 26 +/- 10%).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),%,27,97045,DB00584,Enalapril
,3014110,bioavailability,"Based on the urinary data, the mean +/- SD bioavailability of lisinopril was not different following fasting or fed regimens (27 +/- 15 versus 26 +/- 10%).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),%,26,97046,DB00584,Enalapril
,1310827,unbound,"Results are as follows: mean creatinine clearance, 2.12 mL/s (127 mL/min); mean inulin clearance, 119.1 ml/min mean creatinine clearance/inulin clearance, 1.07 mean enalaprilat protein binding, 37.9% unbound enalaprilat clearance, 222.4 ml/min; and the mean fractional enalaprilat clearances were: enalaprilat clearance/creatinine clearance, 1.72 (P less than 0.05, difference from 1.0); enalaprilat clearance/inulin clearance, 1.85, (P less than 0.05, difference from 1.0).",Renal handling of enalaprilat. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1310827/),%,37.9,99592,DB00584,Enalapril
,1310827,unbound,"Results are as follows: mean creatinine clearance, 2.12 mL/s (127 mL/min); mean inulin clearance, 119.1 ml/min mean creatinine clearance/inulin clearance, 1.07 mean enalaprilat protein binding, 37.9% unbound enalaprilat clearance, 222.4 ml/min; and the mean fractional enalaprilat clearances were: enalaprilat clearance/creatinine clearance, 1.72 (P less than 0.05, difference from 1.0); enalaprilat clearance/inulin clearance, 1.85, (P less than 0.05, difference from 1.0).",Renal handling of enalaprilat. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1310827/),[ml] / [min],222.4,99593,DB00584,Enalapril
,2853960,plasma clearance,4. Haemodialysis plasma clearance was similar for both drugs with mean values of the order of 40 ml min-1.,"Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2853960/),[ml] / [min],40,100439,DB00584,Enalapril
,17324140,area under the time-course curve (AUC(0-24h)),"3. In the NCX899 group, the area under the time-course curve (AUC(0-24h)) was 29.18 +/- 4.72, 229.37 +/- 51.32 and 5159.23 +/- 514.88 microg.h/L for the analytes nitro-enalapril, enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],29.18,102296,DB00584,Enalapril
,17324140,area under the time-course curve (AUC(0-24h)),"3. In the NCX899 group, the area under the time-course curve (AUC(0-24h)) was 29.18 +/- 4.72, 229.37 +/- 51.32 and 5159.23 +/- 514.88 microg.h/L for the analytes nitro-enalapril, enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],229.37,102297,DB00584,Enalapril
,17324140,area under the time-course curve (AUC(0-24h)),"3. In the NCX899 group, the area under the time-course curve (AUC(0-24h)) was 29.18 +/- 4.72, 229.37 +/- 51.32 and 5159.23 +/- 514.88 microg.h/L for the analytes nitro-enalapril, enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],5159.23,102298,DB00584,Enalapril
,17324140,AUC(0-24h),"In the enalapril group, the AUC(0-24h) was 704.53 +/- 158.86 and 4149.27 +/- 847.30 microg.h/L for the analytes enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],704.53,102299,DB00584,Enalapril
,17324140,AUC(0-24h),"In the enalapril group, the AUC(0-24h) was 704.53 +/- 158.86 and 4149.27 +/- 847.30 microg.h/L for the analytes enalapril and enalaprilat, respectively.",Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324140/),[h·μg] / [l],4149.27,102300,DB00584,Enalapril
,12852442,absorption half-life,"The absorption half-life of the investigated drugs ranged from 2 to 59 min, and the extent of absorption from 21 to 94% in 2 h in the isolated perfused rat lung model.",Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852442/),min,2 to 59,102577,DB00584,Enalapril
,10919340,C,"Cumulative urinary recovery of free enalaprilat (0 - 72 hours) was similar between the wafer and conventional tablet formulations (arithmetic mean 5.13 vs. 5.03 mg, about 36% of dose).","Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919340/),mg,5.13,103680,DB00584,Enalapril
,10919340,urinary recovery,"Cumulative urinary recovery of free enalaprilat (0 - 72 hours) was similar between the wafer and conventional tablet formulations (arithmetic mean 5.13 vs. 5.03 mg, about 36% of dose).","Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919340/),mg,5.13,103681,DB00584,Enalapril
,10919340,urinary recovery,"Cumulative urinary recovery of free enalaprilat (0 - 72 hours) was similar between the wafer and conventional tablet formulations (arithmetic mean 5.13 vs. 5.03 mg, about 36% of dose).","Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919340/),mg,5.03,103682,DB00584,Enalapril
,10919340,Cmax,Cmax of serum enalaprilat was also similar between the wafer and conventional tablet formulations (arithmetic mean 85.7 vs. 76.3 ng/ml).,"Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919340/),[ng] / [ml],85.7,103683,DB00584,Enalapril
,10919340,Cmax,Cmax of serum enalaprilat was also similar between the wafer and conventional tablet formulations (arithmetic mean 85.7 vs. 76.3 ng/ml).,"Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919340/),[ng] / [ml],76.3,103684,DB00584,Enalapril
,10919340,Cmax ratio,"The geometric mean Cmax ratio (wafer: tablet) was 1. 10 (90% CI: 1.00, 1.22).","Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919340/),,1. 10,103685,DB00584,Enalapril
,8061850,terminal half-life,"After intravenous infusion, the disposition of spirapril is monophasic with a terminal half-life of 20-50 minutes.",Spirapril: pharmacokinetic properties and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),min,20-50,108588,DB00584,Enalapril
,8061850,Plasma clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],56,108589,DB00584,Enalapril
,8061850,renal clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],11,108590,DB00584,Enalapril
,8061850,volume of distribution,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,28,108591,DB00584,Enalapril
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,2,108592,DB00584,Enalapril
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,35,108593,DB00584,Enalapril
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],10,108594,DB00584,Enalapril
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],7.6,108595,DB00584,Enalapril
,8061850,volume of distribution,The volume of distribution was 43 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,43,108596,DB00584,Enalapril
,8061850,bioavailability,The bioavailability of orally administered spirapril was 50% whereas the bioavailability of orally administered spiraprilat was virtually zero.,Spirapril: pharmacokinetic properties and drug interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),%,50,108597,DB00584,Enalapril
,24368107,lag time,An obvious 4h lag time period and rapid drug release was observed from in vitro dissolution profiles.,A novel pulsatile drug delivery system based on the physiochemical reaction between acrylic copolymer and organic acid: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368107/),h,4,109396,DB00584,Enalapril
,24368107,AUC0-τ,"The AUC0-τ of the EM pulsatile pellets and the market tablets was 702.384 ± 96.89 1 hn g/mL and 810.817 ± 67.712 h ng/mL, while the relative bioavailability was 86.62%.",A novel pulsatile drug delivery system based on the physiochemical reaction between acrylic copolymer and organic acid: in vitro and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368107/),[1·g·hn] / [ml],702.384,109397,DB00584,Enalapril
,24368107,AUC0-τ,"The AUC0-τ of the EM pulsatile pellets and the market tablets was 702.384 ± 96.89 1 hn g/mL and 810.817 ± 67.712 h ng/mL, while the relative bioavailability was 86.62%.",A novel pulsatile drug delivery system based on the physiochemical reaction between acrylic copolymer and organic acid: in vitro and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368107/),[h·ng] / [ml],810.817,109398,DB00584,Enalapril
,24368107,relative bioavailability,"The AUC0-τ of the EM pulsatile pellets and the market tablets was 702.384 ± 96.89 1 hn g/mL and 810.817 ± 67.712 h ng/mL, while the relative bioavailability was 86.62%.",A novel pulsatile drug delivery system based on the physiochemical reaction between acrylic copolymer and organic acid: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368107/),%,86.62,109399,DB00584,Enalapril
,6100874,half-life for accumulation,The half-life for accumulation is approximately 11 h.,Clinical pharmacology of enalapril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6100874/),h,11,113589,DB00584,Enalapril
,12869367,Metabolic clearance rates,"Metabolic clearance rates were higher for ANG III and ANG IV (391 +/- 19 and 274 +/- 13 ml.kg-1.min-1, respectively) than for ANG II (107 +/- 13 ml.kg-1.min-1).","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),[ml] / [kg·min],391,114797,DB00584,Enalapril
,12869367,Metabolic clearance rates,"Metabolic clearance rates were higher for ANG III and ANG IV (391 +/- 19 and 274 +/- 13 ml.kg-1.min-1, respectively) than for ANG II (107 +/- 13 ml.kg-1.min-1).","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),[ml] / [kg·min],274,114798,DB00584,Enalapril
,12869367,Metabolic clearance rates,"Metabolic clearance rates were higher for ANG III and ANG IV (391 +/- 19 and 274 +/- 13 ml.kg-1.min-1, respectively) than for ANG II (107 +/- 13 ml.kg-1.min-1).","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),[ml] / [kg·min],107,114799,DB00584,Enalapril
,12869367,sodium excretion,"ANG II increased ANG IR by 60 +/- 7 pmol/ml, blood pressure by 30%, increased plasma aldosterone markedly (to 345 +/- 72 pg/ml), and plasma vasopressin transiently, while reducing glomerular filtration rate (40 +/- 2 to 33 +/- 2 ml/min), sodium excretion (50 +/- 7 to 16 +/- 4 micromol/min), and urine flow.","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),,50,114800,DB00584,Enalapril
,12869367,sodium excretion,"ANG II increased ANG IR by 60 +/- 7 pmol/ml, blood pressure by 30%, increased plasma aldosterone markedly (to 345 +/- 72 pg/ml), and plasma vasopressin transiently, while reducing glomerular filtration rate (40 +/- 2 to 33 +/- 2 ml/min), sodium excretion (50 +/- 7 to 16 +/- 4 micromol/min), and urine flow.","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),,16,114801,DB00584,Enalapril
,12165071,area under the curve (AUC(0)--> infinity ),"The enalapril values for the area under the curve (AUC(0)--> infinity ) were 480 +/- 216 and 832 +/- 325 ngh/mL, maximum plasma concentrations (C(max)) were 310 +/- 187 and 481 +/- 185 ng/mL, and times required to reach the maximum concentration t(max) were 1.13 +/- 0.22 and 1.09 +/- 0.33 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),[ngh] / [ml],480,121292,DB00584,Enalapril
,12165071,area under the curve (AUC(0)--> infinity ),"The enalapril values for the area under the curve (AUC(0)--> infinity ) were 480 +/- 216 and 832 +/- 325 ngh/mL, maximum plasma concentrations (C(max)) were 310 +/- 187 and 481 +/- 185 ng/mL, and times required to reach the maximum concentration t(max) were 1.13 +/- 0.22 and 1.09 +/- 0.33 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),[ngh] / [ml],832,121293,DB00584,Enalapril
,12165071,maximum plasma concentrations (C(max)),"The enalapril values for the area under the curve (AUC(0)--> infinity ) were 480 +/- 216 and 832 +/- 325 ngh/mL, maximum plasma concentrations (C(max)) were 310 +/- 187 and 481 +/- 185 ng/mL, and times required to reach the maximum concentration t(max) were 1.13 +/- 0.22 and 1.09 +/- 0.33 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),[ng] / [ml],310,121294,DB00584,Enalapril
,12165071,maximum plasma concentrations (C(max)),"The enalapril values for the area under the curve (AUC(0)--> infinity ) were 480 +/- 216 and 832 +/- 325 ngh/mL, maximum plasma concentrations (C(max)) were 310 +/- 187 and 481 +/- 185 ng/mL, and times required to reach the maximum concentration t(max) were 1.13 +/- 0.22 and 1.09 +/- 0.33 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),[ng] / [ml],481,121295,DB00584,Enalapril
,12165071,times required to reach the maximum concentration t(max),"The enalapril values for the area under the curve (AUC(0)--> infinity ) were 480 +/- 216 and 832 +/- 325 ngh/mL, maximum plasma concentrations (C(max)) were 310 +/- 187 and 481 +/- 185 ng/mL, and times required to reach the maximum concentration t(max) were 1.13 +/- 0.22 and 1.09 +/- 0.33 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),h,1.13,121296,DB00584,Enalapril
,12165071,times required to reach the maximum concentration t(max),"The enalapril values for the area under the curve (AUC(0)--> infinity ) were 480 +/- 216 and 832 +/- 325 ngh/mL, maximum plasma concentrations (C(max)) were 310 +/- 187 and 481 +/- 185 ng/mL, and times required to reach the maximum concentration t(max) were 1.13 +/- 0.22 and 1.09 +/- 0.33 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),h,1.09,121297,DB00584,Enalapril
,12165071,AUC(0)--> infinity,"The enalaprilat values for AUC(0)--> infinity were 256 +/- 122 and 383 +/- 158 ngh/mL, C(max) values were 57 +/- 29 and 72.9 +/- 33.6 ng/mL and t(max) values were 4.28 +/- 1.45 and 4.05 +/- 01.22 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),[ngh] / [ml],256,121298,DB00584,Enalapril
,12165071,AUC(0)--> infinity,"The enalaprilat values for AUC(0)--> infinity were 256 +/- 122 and 383 +/- 158 ngh/mL, C(max) values were 57 +/- 29 and 72.9 +/- 33.6 ng/mL and t(max) values were 4.28 +/- 1.45 and 4.05 +/- 01.22 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),[ngh] / [ml],383,121299,DB00584,Enalapril
,12165071,C(max),"The enalaprilat values for AUC(0)--> infinity were 256 +/- 122 and 383 +/- 158 ngh/mL, C(max) values were 57 +/- 29 and 72.9 +/- 33.6 ng/mL and t(max) values were 4.28 +/- 1.45 and 4.05 +/- 01.22 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),[ng] / [ml],57,121300,DB00584,Enalapril
,12165071,C(max),"The enalaprilat values for AUC(0)--> infinity were 256 +/- 122 and 383 +/- 158 ngh/mL, C(max) values were 57 +/- 29 and 72.9 +/- 33.6 ng/mL and t(max) values were 4.28 +/- 1.45 and 4.05 +/- 01.22 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),[ng] / [ml],72.9,121301,DB00584,Enalapril
,12165071,t(max),"The enalaprilat values for AUC(0)--> infinity were 256 +/- 122 and 383 +/- 158 ngh/mL, C(max) values were 57 +/- 29 and 72.9 +/- 33.6 ng/mL and t(max) values were 4.28 +/- 1.45 and 4.05 +/- 01.22 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),h,4.28,121302,DB00584,Enalapril
,12165071,t(max),"The enalaprilat values for AUC(0)--> infinity were 256 +/- 122 and 383 +/- 158 ngh/mL, C(max) values were 57 +/- 29 and 72.9 +/- 33.6 ng/mL and t(max) values were 4.28 +/- 1.45 and 4.05 +/- 01.22 h for 10 and 20 mg doses, respectively.",Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165071/),h,4.05,121303,DB00584,Enalapril
,15985045,AUC(o-->infinity),"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),[h·ng] / [ml],450.0,122087,DB00584,Enalapril
,15985045,AUC(o-->infinity),"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),[h·ng] / [ml],479.6,122088,DB00584,Enalapril
,15985045,Cmax,"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),[ng] / [ml],313.5,122089,DB00584,Enalapril
,15985045,Cmax,"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),[ng] / [ml],310.1,122090,DB00584,Enalapril
,15985045,Tmax,"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),h,1.06,122091,DB00584,Enalapril
,15985045,Tmax,"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),h,1.13,122092,DB00584,Enalapril
,15985045,t1/2,"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),h,0.3 to 6.1,122093,DB00584,Enalapril
,15985045,t1/2,"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),,1.6,122094,DB00584,Enalapril
,15985045,t1/2,"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),h,0.40 to 5.05,122095,DB00584,Enalapril
,15985045,t1/2,"For enalapril, the AUC(o-->infinity) values (Mean+/-SD) were 450.0+/-199.5 and 479.6+/-215.6 ng h/mL, Cmax values were 313.5+/-139.6 and 310.1+/-186.6 ng/mL, Tmax values were 1.06+/-0.30 h and 1.13+/-0.22 h, and t1/2 ranged between 0.3 to 6.1 h (1.6+/-1.5) and 0.40 to 5.05 h (1.3+/-1.0), for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),,1.3,122096,DB00584,Enalapril
,15985045,AUC(o-->infinity),"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),[h·ng] / [ml],266.9,122097,DB00584,Enalapril
,15985045,AUC(o-->infinity),"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),[h·ng] / [ml],255.9,122098,DB00584,Enalapril
,15985045,Cmax,"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),[ng] / [ml],54.8,122099,DB00584,Enalapril
,15985045,Cmax,"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),[ng] / [ml],57.2,122100,DB00584,Enalapril
,15985045,Tmax,"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),h,4.6,122101,DB00584,Enalapril
,15985045,Tmax,"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),h,4.3,122102,DB00584,Enalapril
,15985045,t1/2,"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),h,1.1 to 10.5,122103,DB00584,Enalapril
,15985045,t1/2,"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),,4.5,122104,DB00584,Enalapril
,15985045,t1/2,"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),h,0.6 to 9.4,122105,DB00584,Enalapril
,15985045,t1/2,"For enalaprilat, the AUC(o-->infinity) values were 266.9+/-122.7 and 255.9+/-121.8 ng h/ml, Cmax values were 54.8+/-29.5 and 57.2+/-29.0 ng/mL, Tmax values were 4.6+/-1.6 h and 4.3+/-1.45 h, and t1/2 ranged between 1.1 to 10.5 h (4.5+/-2.9) and 0.6 to 9.4 h (3.5+/-2.5) for the two brands.",Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985045/),,3.5,122106,DB00584,Enalapril
,24972864,elimination half-lives,The elimination half-lives of enalapril and enalaprilat were 0.67 and 2.76 h respectively after IV enalapril.,"Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24972864/),h,0.67,122735,DB00584,Enalapril
,24972864,elimination half-lives,The elimination half-lives of enalapril and enalaprilat were 0.67 and 2.76 h respectively after IV enalapril.,"Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24972864/),h,2.76,122736,DB00584,Enalapril
,24972864,Maximum,"Maximum mean ACE inhibitions from baseline were 88.38, 3.24, 21.69, 26.11 and 30.19% for IV enalapril at 0.50 mg/kg, placebo and PO enalapril at 0.50, 1.00 and 2.00 mg/kg, respectively.","Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24972864/),%,88.38,122737,DB00584,Enalapril
,24972864,inhibitions,"Maximum mean ACE inhibitions from baseline were 88.38, 3.24, 21.69, 26.11 and 30.19% for IV enalapril at 0.50 mg/kg, placebo and PO enalapril at 0.50, 1.00 and 2.00 mg/kg, respectively.","Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24972864/),%,88.38,122738,DB00584,Enalapril
,24972864,inhibitions,"Maximum mean ACE inhibitions from baseline were 88.38, 3.24, 21.69, 26.11 and 30.19% for IV enalapril at 0.50 mg/kg, placebo and PO enalapril at 0.50, 1.00 and 2.00 mg/kg, respectively.","Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24972864/),%,3.24,122739,DB00584,Enalapril
,24972864,inhibitions,"Maximum mean ACE inhibitions from baseline were 88.38, 3.24, 21.69, 26.11 and 30.19% for IV enalapril at 0.50 mg/kg, placebo and PO enalapril at 0.50, 1.00 and 2.00 mg/kg, respectively.","Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24972864/),%,21.69,122740,DB00584,Enalapril
,24972864,inhibitions,"Maximum mean ACE inhibitions from baseline were 88.38, 3.24, 21.69, 26.11 and 30.19% for IV enalapril at 0.50 mg/kg, placebo and PO enalapril at 0.50, 1.00 and 2.00 mg/kg, respectively.","Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24972864/),%,26.11,122741,DB00584,Enalapril
,24972864,inhibitions,"Maximum mean ACE inhibitions from baseline were 88.38, 3.24, 21.69, 26.11 and 30.19% for IV enalapril at 0.50 mg/kg, placebo and PO enalapril at 0.50, 1.00 and 2.00 mg/kg, respectively.","Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24972864/),%,30.19,122742,DB00584,Enalapril
,15761754,trough concentration,"In the high-concentration group, the median enalaprilat trough concentration was 92.9 ng/ml (21.8-371.0 ng/ml) and in the low-concentration group it was 9.1 ng/ml (2.5-74.8 ng/ml) at 3 months follow-up (P<0.001).","Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761754/),[ng] / [ml],92.9,124152,DB00584,Enalapril
,15761754,trough concentration,"In the high-concentration group, the median enalaprilat trough concentration was 92.9 ng/ml (21.8-371.0 ng/ml) and in the low-concentration group it was 9.1 ng/ml (2.5-74.8 ng/ml) at 3 months follow-up (P<0.001).","Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761754/),[ng] / [ml],9.1,124153,DB00584,Enalapril
,33963573,Cmax,The CES1 G143E carriers had 30.9% lower enalaprilat Cmax (P = 0.03) compared to the non-carriers (38.01 vs. 55.01 ng/mL).,Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33963573/),[ng] / [ml],38.01,133422,DB00584,Enalapril
,33963573,Cmax,The CES1 G143E carriers had 30.9% lower enalaprilat Cmax (P = 0.03) compared to the non-carriers (38.01 vs. 55.01 ng/mL).,Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33963573/),[ng] / [ml],55.01,133423,DB00584,Enalapril
,33963573,AUC0-∞,The carrier group had 27.5% lower AUC0-∞ (P = 0.02) of plasma enalaprilat compared to the non-carriers (374.29 vs. 515.91 ng*h/mL).,Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33963573/),[h·ng] / [ml],374.29,133424,DB00584,Enalapril
,33963573,AUC0-∞,The carrier group had 27.5% lower AUC0-∞ (P = 0.02) of plasma enalaprilat compared to the non-carriers (374.29 vs. 515.91 ng*h/mL).,Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33963573/),[h·ng] / [ml],515.91,133425,DB00584,Enalapril
,2844083,oral bioavailability,"The angiotensin-converting enzyme inhibitor, lisinopril, has an oral bioavailability of 25 percent +/- 4 percent, which is unaffected by food.",Pharmacokinetics of lisinopril. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844083/),%,25,139309,DB00584,Enalapril
,2844083,accumulation half-life,The accumulation half-life averages 12.6 hours despite a terminal serum half-life of approximately 40 hours.,Pharmacokinetics of lisinopril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844083/),h,12.6,139310,DB00584,Enalapril
,2844083,terminal serum half-life,The accumulation half-life averages 12.6 hours despite a terminal serum half-life of approximately 40 hours.,Pharmacokinetics of lisinopril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844083/),h,40,139311,DB00584,Enalapril
,1442135,Clearance,"Clearance of creatinine and excretion of urea decreased (39 +/- 4 to 29 +/- 3 ml min-1 and 87 +/- 16 to 71 +/- 14 mumol min-1, respectively).","Effects, release and disposal of endothelin-1 in conscious dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),[ml] / [min],39,139950,DB00584,Enalapril
,1442135,excretion,"Clearance of creatinine and excretion of urea decreased (39 +/- 4 to 29 +/- 3 ml min-1 and 87 +/- 16 to 71 +/- 14 mumol min-1, respectively).","Effects, release and disposal of endothelin-1 in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),[ml] / [min],29,139951,DB00584,Enalapril
,1442135,excretion,"Clearance of creatinine and excretion of urea decreased (39 +/- 4 to 29 +/- 3 ml min-1 and 87 +/- 16 to 71 +/- 14 mumol min-1, respectively).","Effects, release and disposal of endothelin-1 in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),[μM] / [min],87,139952,DB00584,Enalapril
,1442135,excretion,"Clearance of creatinine and excretion of urea decreased (39 +/- 4 to 29 +/- 3 ml min-1 and 87 +/- 16 to 71 +/- 14 mumol min-1, respectively).","Effects, release and disposal of endothelin-1 in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),[μM] / [min],71,139953,DB00584,Enalapril
,1442135,initial t1/2,"Decay curves for ET-1 in venous and arterial plasma were identical, and initial t1/2 was 1.1 +/- 0.1 min.","Effects, release and disposal of endothelin-1 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),min,1.1,139954,DB00584,Enalapril
,15058776,elimination half lives,"The elimination half lives of enalapril and enalaprilat were 0.59 and 1.25 hours, respectively, after i.v. administration.","Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058776/),h,0.59,142787,DB00584,Enalapril
,15058776,elimination half lives,"The elimination half lives of enalapril and enalaprilat were 0.59 and 1.25 hours, respectively, after i.v. administration.","Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058776/),h,1.25,142788,DB00584,Enalapril
,1330574,Ki,"The relationships between serum enalaprilat and serum ACE activity were similar after both treatments, both consistent with a value for Ki of enalaprilat of about 0.1 nmol.l-1.",The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330574/),[nM] / [l],0.1,144780,DB00584,Enalapril
,19071268,m/z,The acquisition was performed in the multiple reaction monitoring mode; monitoring the transitions: m/z 418.4>211.1 for cilazapril and m/z 390.3>211.1 for cilazaprilat.,A liquid chromatography/positive ion tandem mass spectrometry method for the determination of cilazapril and cilazaprilat in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19071268/),,418.4,146891,DB00584,Enalapril
,19071268,m/z,The acquisition was performed in the multiple reaction monitoring mode; monitoring the transitions: m/z 418.4>211.1 for cilazapril and m/z 390.3>211.1 for cilazaprilat.,A liquid chromatography/positive ion tandem mass spectrometry method for the determination of cilazapril and cilazaprilat in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19071268/),,211.1,146892,DB00584,Enalapril
,19071268,m/z,The acquisition was performed in the multiple reaction monitoring mode; monitoring the transitions: m/z 418.4>211.1 for cilazapril and m/z 390.3>211.1 for cilazaprilat.,A liquid chromatography/positive ion tandem mass spectrometry method for the determination of cilazapril and cilazaprilat in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19071268/),,390.3,146893,DB00584,Enalapril
,11583474,urinary recovery,"For children ages 2 to 15 years, mean urinary recovery of total enalaprilat ranged from 58.3% in children ages 6 to < 12 years to 71.4% in children ages 12 to < 16 years.",The pharmacokinetics of enalapril in children and infants with hypertension. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583474/),%,58.3,148920,DB00584,Enalapril
,11583474,urinary recovery,"For children ages 2 to 15 years, mean urinary recovery of total enalaprilat ranged from 58.3% in children ages 6 to < 12 years to 71.4% in children ages 12 to < 16 years.",The pharmacokinetics of enalapril in children and infants with hypertension. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583474/),%,71.4,148921,DB00584,Enalapril
,11583474,Urinary recovery,Urinary recovery for children ages 2 to < 6 years was 66.8%.,The pharmacokinetics of enalapril in children and infants with hypertension. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583474/),%,66.8,148922,DB00584,Enalapril
,11583474,effective half-life for accumulation,The median effective half-life for accumulation ranged from 14.6 hours in children ages 12 to < 16 years to 16.3 hours in children ages 6 to < 12 years.,The pharmacokinetics of enalapril in children and infants with hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583474/),h,14.6,148923,DB00584,Enalapril
,11583474,effective half-life for accumulation,The median effective half-life for accumulation ranged from 14.6 hours in children ages 12 to < 16 years to 16.3 hours in children ages 6 to < 12 years.,The pharmacokinetics of enalapril in children and infants with hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583474/),h,16.3,148924,DB00584,Enalapril
,11596205,flow rate,"Chromatographic separation was achieved on a Spherisorb C8 column (200 mm x 4.6 mm, 5 microns), with ethanol--water--10% H3PO4--triethylamine (30:70:1.5:0.1) at a flow rate of 1.0 ml.min-1.",[Solid phase extraction and high performance liquid chromatographic determination of enalapril in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596205/),[ml] / [min],1.0,149874,DB00584,Enalapril
,11596205,detection limit,ml-1 with regression coefficient of 0.997 and detection limit of 1.5 ng.,[Solid phase extraction and high performance liquid chromatographic determination of enalapril in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596205/),ng,1.5,149875,DB00584,Enalapril
>,11596205,recovery,"The within-day RSD and between-day RSD were < 8.73%, the recovery of method > 91.6%.",[Solid phase extraction and high performance liquid chromatographic determination of enalapril in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596205/),%,91.6,149876,DB00584,Enalapril
,16948800,immunoactivity,Angiotensin immunoactivity in plasma increased to 60 +/- 10 pg mL(-1) during infusion of AngII or infusion of AngIII.,Systemic effects of angiotensin III in conscious dogs during acute double blockade of the renin-angiotensin-aldosterone-system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16948800/),[pg] / [ml],60,159656,DB00584,Enalapril
,2442558,urinary recovery,Mean urinary recovery of lisinopril was found to be 15% following oral administration and 88% following intravenous administration.,"Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2442558/),%,15,170982,DB00584,Enalapril
,2442558,urinary recovery,Mean urinary recovery of lisinopril was found to be 15% following oral administration and 88% following intravenous administration.,"Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2442558/),%,88,170983,DB00584,Enalapril
> or =,11185637,Trough/peak DBP ratios,Trough/peak DBP ratios were > or = 85% for all telmisartan doses versus 65% for enalapril.,Dose response and safety of telmisartan in patients with mild to moderate hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185637/),%,85,171226,DB00584,Enalapril
,11185637,Trough/peak DBP ratios,Trough/peak DBP ratios were > or = 85% for all telmisartan doses versus 65% for enalapril.,Dose response and safety of telmisartan in patients with mild to moderate hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185637/),%,65,171227,DB00584,Enalapril
,11185637,Cmax,"For example, mean +/- SD values for Cmax were 159 +/- 104 ng/mL for telmisartan 40 mg, 693 +/- 606 ng/mL for telmisartan 80 mg, and 1635 +/- 1406 ng/mL for telmisartan 120 mg.",Dose response and safety of telmisartan in patients with mild to moderate hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185637/),[ng] / [ml],159,171228,DB00584,Enalapril
,11185637,Cmax,"For example, mean +/- SD values for Cmax were 159 +/- 104 ng/mL for telmisartan 40 mg, 693 +/- 606 ng/mL for telmisartan 80 mg, and 1635 +/- 1406 ng/mL for telmisartan 120 mg.",Dose response and safety of telmisartan in patients with mild to moderate hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185637/),[ng] / [ml],693,171229,DB00584,Enalapril
,11185637,Cmax,"For example, mean +/- SD values for Cmax were 159 +/- 104 ng/mL for telmisartan 40 mg, 693 +/- 606 ng/mL for telmisartan 80 mg, and 1635 +/- 1406 ng/mL for telmisartan 120 mg.",Dose response and safety of telmisartan in patients with mild to moderate hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185637/),[ng] / [ml],1635,171230,DB00584,Enalapril
,2158548,peak serum concentration,"Mean peak serum concentration of enalapril rose from 158 +/- 7 to 216 +/- 1 ng/ml (P less than .01), whereas that of its metabolite, enalaprilat, rose from 62 +/- 6 to 84 +/- 8 ng/ml (P less than .01) in the presence of probenecid pretreatment.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ng] / [ml],158,188341,DB00584,Enalapril
,2158548,peak serum concentration,"Mean peak serum concentration of enalapril rose from 158 +/- 7 to 216 +/- 1 ng/ml (P less than .01), whereas that of its metabolite, enalaprilat, rose from 62 +/- 6 to 84 +/- 8 ng/ml (P less than .01) in the presence of probenecid pretreatment.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ng] / [ml],216,188342,DB00584,Enalapril
,2158548,peak serum concentration,"Mean peak serum concentration of enalapril rose from 158 +/- 7 to 216 +/- 1 ng/ml (P less than .01), whereas that of its metabolite, enalaprilat, rose from 62 +/- 6 to 84 +/- 8 ng/ml (P less than .01) in the presence of probenecid pretreatment.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ng] / [ml],62,188343,DB00584,Enalapril
,2158548,peak serum concentration,"Mean peak serum concentration of enalapril rose from 158 +/- 7 to 216 +/- 1 ng/ml (P less than .01), whereas that of its metabolite, enalaprilat, rose from 62 +/- 6 to 84 +/- 8 ng/ml (P less than .01) in the presence of probenecid pretreatment.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ng] / [ml],84,188344,DB00584,Enalapril
,2158548,renal clearance,The renal clearance of enalapril decreased from 229 +/- 19 to 61 +/- 4 ml/min (P less than .001) and that of enalaprilat from 108 +/- 4 to 66 +/- 2 ml/min (P less than .001).,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ml] / [min],229,188345,DB00584,Enalapril
,2158548,renal clearance,The renal clearance of enalapril decreased from 229 +/- 19 to 61 +/- 4 ml/min (P less than .001) and that of enalaprilat from 108 +/- 4 to 66 +/- 2 ml/min (P less than .001).,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ml] / [min],61,188346,DB00584,Enalapril
,2158548,renal clearance,The renal clearance of enalapril decreased from 229 +/- 19 to 61 +/- 4 ml/min (P less than .001) and that of enalaprilat from 108 +/- 4 to 66 +/- 2 ml/min (P less than .001).,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ml] / [min],108,188347,DB00584,Enalapril
,2158548,renal clearance,The renal clearance of enalapril decreased from 229 +/- 19 to 61 +/- 4 ml/min (P less than .001) and that of enalaprilat from 108 +/- 4 to 66 +/- 2 ml/min (P less than .001).,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ml] / [min],66,188348,DB00584,Enalapril
,2158548,total drug recovery,The total drug recovery fell from 48 +/- 3 to 38 +/- 2% (P less than .01) of the administered dose with no accompanying changes in plasma elimination half-lives of the parent drug or metabolite.,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),%,48,188349,DB00584,Enalapril
,2158548,total drug recovery,The total drug recovery fell from 48 +/- 3 to 38 +/- 2% (P less than .01) of the administered dose with no accompanying changes in plasma elimination half-lives of the parent drug or metabolite.,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),%,38,188350,DB00584,Enalapril
,2158548,Absolute urinary excretion of sodium,"Absolute urinary excretion of sodium increased from 51 +/- 5 to 91 +/- 8 mmol/6 hr (P less than .001) after enalapril and from 55 +/- 4 to 113 +/- 13 mmol/6 hr (P less than .01) after enalapril in presence of probenecid pretreatment, despite a significant decrease in the renal excretion of enalapril and enalaprilat over the same interval.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[mM] / [6·h],51,188351,DB00584,Enalapril
,2158548,Absolute urinary excretion of sodium,"Absolute urinary excretion of sodium increased from 51 +/- 5 to 91 +/- 8 mmol/6 hr (P less than .001) after enalapril and from 55 +/- 4 to 113 +/- 13 mmol/6 hr (P less than .01) after enalapril in presence of probenecid pretreatment, despite a significant decrease in the renal excretion of enalapril and enalaprilat over the same interval.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[mM] / [6·h],91,188352,DB00584,Enalapril
,2158548,Absolute urinary excretion of sodium,"Absolute urinary excretion of sodium increased from 51 +/- 5 to 91 +/- 8 mmol/6 hr (P less than .001) after enalapril and from 55 +/- 4 to 113 +/- 13 mmol/6 hr (P less than .01) after enalapril in presence of probenecid pretreatment, despite a significant decrease in the renal excretion of enalapril and enalaprilat over the same interval.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[mM] / [6·h],55,188353,DB00584,Enalapril
,2158548,Absolute urinary excretion of sodium,"Absolute urinary excretion of sodium increased from 51 +/- 5 to 91 +/- 8 mmol/6 hr (P less than .001) after enalapril and from 55 +/- 4 to 113 +/- 13 mmol/6 hr (P less than .01) after enalapril in presence of probenecid pretreatment, despite a significant decrease in the renal excretion of enalapril and enalaprilat over the same interval.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[mM] / [6·h],113,188354,DB00584,Enalapril
,2154407,Emax,"For the group, Emax was -46.1 +/- 16.5 and -19.7 +/- 3.8 mm Hg for systolic and diastolic blood pressure, respectively, and the corresponding Ce50 values were 66.1 +/- 20.2 and 61.6 +/- 22.5 ng/ml.",Kinetic-dynamic relations and individual responses to enalapril. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),hg·mm,-,190432,DB00584,Enalapril
,2154407,Emax,"For the group, Emax was -46.1 +/- 16.5 and -19.7 +/- 3.8 mm Hg for systolic and diastolic blood pressure, respectively, and the corresponding Ce50 values were 66.1 +/- 20.2 and 61.6 +/- 22.5 ng/ml.",Kinetic-dynamic relations and individual responses to enalapril. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),hg·mm,46.1,190433,DB00584,Enalapril
,2154407,Emax,"For the group, Emax was -46.1 +/- 16.5 and -19.7 +/- 3.8 mm Hg for systolic and diastolic blood pressure, respectively, and the corresponding Ce50 values were 66.1 +/- 20.2 and 61.6 +/- 22.5 ng/ml.",Kinetic-dynamic relations and individual responses to enalapril. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),hg·mm,19.7,190434,DB00584,Enalapril
,2154407,Ce50,"For the group, Emax was -46.1 +/- 16.5 and -19.7 +/- 3.8 mm Hg for systolic and diastolic blood pressure, respectively, and the corresponding Ce50 values were 66.1 +/- 20.2 and 61.6 +/- 22.5 ng/ml.",Kinetic-dynamic relations and individual responses to enalapril. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),[ng] / [ml],66.1,190435,DB00584,Enalapril
,2154407,Ce50,"For the group, Emax was -46.1 +/- 16.5 and -19.7 +/- 3.8 mm Hg for systolic and diastolic blood pressure, respectively, and the corresponding Ce50 values were 66.1 +/- 20.2 and 61.6 +/- 22.5 ng/ml.",Kinetic-dynamic relations and individual responses to enalapril. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),[ng] / [ml],61.6,190436,DB00584,Enalapril
,2154407,Emax,"For angiotensin converting enzyme inhibition, Emax (%) and Ce50 (ng/ml) were, respectively, 102.4 +/- 5 and 19.8 +/- 13 after the first dose, 103 +/- 5 and 33.4 +/- 20.3 after 1 week, and 101.3 +/- 2.2 and 31.3 +/- 18.9 after 6 weeks.",Kinetic-dynamic relations and individual responses to enalapril. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),[ng] / [ml],102.4,190437,DB00584,Enalapril
,2154407,Ce50,"For angiotensin converting enzyme inhibition, Emax (%) and Ce50 (ng/ml) were, respectively, 102.4 +/- 5 and 19.8 +/- 13 after the first dose, 103 +/- 5 and 33.4 +/- 20.3 after 1 week, and 101.3 +/- 2.2 and 31.3 +/- 18.9 after 6 weeks.",Kinetic-dynamic relations and individual responses to enalapril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),[ng] / [ml],102.4,190438,DB00584,Enalapril
,2154407,Ce50,"For angiotensin converting enzyme inhibition, Emax (%) and Ce50 (ng/ml) were, respectively, 102.4 +/- 5 and 19.8 +/- 13 after the first dose, 103 +/- 5 and 33.4 +/- 20.3 after 1 week, and 101.3 +/- 2.2 and 31.3 +/- 18.9 after 6 weeks.",Kinetic-dynamic relations and individual responses to enalapril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),[ng] / [ml],19.8,190439,DB00584,Enalapril
,2154407,Ce50,"For angiotensin converting enzyme inhibition, Emax (%) and Ce50 (ng/ml) were, respectively, 102.4 +/- 5 and 19.8 +/- 13 after the first dose, 103 +/- 5 and 33.4 +/- 20.3 after 1 week, and 101.3 +/- 2.2 and 31.3 +/- 18.9 after 6 weeks.",Kinetic-dynamic relations and individual responses to enalapril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),[ng] / [ml],103,190440,DB00584,Enalapril
,2154407,Ce50,"For angiotensin converting enzyme inhibition, Emax (%) and Ce50 (ng/ml) were, respectively, 102.4 +/- 5 and 19.8 +/- 13 after the first dose, 103 +/- 5 and 33.4 +/- 20.3 after 1 week, and 101.3 +/- 2.2 and 31.3 +/- 18.9 after 6 weeks.",Kinetic-dynamic relations and individual responses to enalapril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),[ng] / [ml],33.4,190441,DB00584,Enalapril
,2154407,Ce50,"For angiotensin converting enzyme inhibition, Emax (%) and Ce50 (ng/ml) were, respectively, 102.4 +/- 5 and 19.8 +/- 13 after the first dose, 103 +/- 5 and 33.4 +/- 20.3 after 1 week, and 101.3 +/- 2.2 and 31.3 +/- 18.9 after 6 weeks.",Kinetic-dynamic relations and individual responses to enalapril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),[ng] / [ml],101.3,190442,DB00584,Enalapril
,2154407,Ce50,"For angiotensin converting enzyme inhibition, Emax (%) and Ce50 (ng/ml) were, respectively, 102.4 +/- 5 and 19.8 +/- 13 after the first dose, 103 +/- 5 and 33.4 +/- 20.3 after 1 week, and 101.3 +/- 2.2 and 31.3 +/- 18.9 after 6 weeks.",Kinetic-dynamic relations and individual responses to enalapril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2154407/),[ng] / [ml],31.3,190443,DB00584,Enalapril
,1712266,half-life,"Using this method, we showed that single oral doses of cilazapril 4 mg, captopril 25 mg and enalapril 10mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacological half-life of about 4 hours for cilazapril.",Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712266/),h,4,192097,DB00584,Enalapril
,1712266,apparent Ki-dose,"The dose representing 50% inhibition of ACE activity (apparent Ki-dose) was about 0.6mg, 3 hours after cilazapril administration.",Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712266/),mg,0.6,192098,DB00584,Enalapril
,17145205,retention time,"The retention time was 1.45 and 1.37 min for captopril and enalapril, respectively.","Determination of captopril in human plasma, using solid phase extraction and high-performance liquid chromatography, coupled to mass spectrometry: application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145205/),min,1.45,194617,DB00584,Enalapril
,17145205,retention time,"The retention time was 1.45 and 1.37 min for captopril and enalapril, respectively.","Determination of captopril in human plasma, using solid phase extraction and high-performance liquid chromatography, coupled to mass spectrometry: application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145205/),min,1.37,194618,DB00584,Enalapril
,17145205,overall mean recovery,"The overall mean recovery, using SPE extraction with OASIS HLB cartridges, was found to be 107.2+/-9.5 and 100.04+/-2%, respectively.","Determination of captopril in human plasma, using solid phase extraction and high-performance liquid chromatography, coupled to mass spectrometry: application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145205/),%,107.2,194619,DB00584,Enalapril
,17145205,overall mean recovery,"The overall mean recovery, using SPE extraction with OASIS HLB cartridges, was found to be 107.2+/-9.5 and 100.04+/-2%, respectively.","Determination of captopril in human plasma, using solid phase extraction and high-performance liquid chromatography, coupled to mass spectrometry: application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145205/),%,100.04,194620,DB00584,Enalapril
>,28894622,Stability,"Stability was >85% and the LOD was 0.907 and 0.910 ng/ml for enalapril and enalaprilat, respectively, and LLOQ was 1 ng/ml.",A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28894622/),%,85,197294,DB00584,Enalapril
,28894622,LOD,"Stability was >85% and the LOD was 0.907 and 0.910 ng/ml for enalapril and enalaprilat, respectively, and LLOQ was 1 ng/ml.",A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28894622/),[ng] / [ml],0.907,197295,DB00584,Enalapril
,28894622,LOD,"Stability was >85% and the LOD was 0.907 and 0.910 ng/ml for enalapril and enalaprilat, respectively, and LLOQ was 1 ng/ml.",A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28894622/),[ng] / [ml],0.910,197296,DB00584,Enalapril
,2547465,half-life for the terminal phase,The half-life for the terminal phase (approximately 40 h) was not predictive of steady-state parameters when ten daily doses (q24h) of lisinopril were administered orally to healthy volunteers.,Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547465/),h,40,197547,DB00584,Enalapril
,2547465,effective half-life for accumulation,The mean effective half-life for accumulation was 12.6 h.,Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547465/),h,12.6,197548,DB00584,Enalapril
,2547465,accumulation ratio,The mean accumulation ratio was 1.38.,Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547465/),,1.38,197549,DB00584,Enalapril
,2068835,elimination half-life,"The elimination half-life of quinaprilat is three hours, but is prolonged up to 11 hours in patients with renal dysfunction.",Quinapril: a new second-generation ACE inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2068835/),h,three,203266,DB00584,Enalapril
,2068835,elimination half-life,"The elimination half-life of quinaprilat is three hours, but is prolonged up to 11 hours in patients with renal dysfunction.",Quinapril: a new second-generation ACE inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2068835/),h,11,203267,DB00584,Enalapril
,10052059,area under the curve (AUC),The area under the curve (AUC) for enalaprilat increased after surgery from 23.6 +/- 14.7 to 42.4 +/- 20.9 micrograms.minute/mL (P < .01).,"Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[min·μg] / [ml],23.6,207016,DB00584,Enalapril
,10052059,area under the curve (AUC),The area under the curve (AUC) for enalaprilat increased after surgery from 23.6 +/- 14.7 to 42.4 +/- 20.9 micrograms.minute/mL (P < .01).,"Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[min·μg] / [ml],42.4,207017,DB00584,Enalapril
,10052059,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) was increased in the impaired dogs (59.1 +/- 23.3 versus 43.9 +/- 32.9 ng/mL), but this variation was not significant (P > .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[ng] / [ml],59.1,207018,DB00584,Enalapril
,10052059,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) was increased in the impaired dogs (59.1 +/- 23.3 versus 43.9 +/- 32.9 ng/mL), but this variation was not significant (P > .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[ng] / [ml],43.9,207019,DB00584,Enalapril
,10052059,AUC,"Renal failure had no significant effect on AUC for benazeprilat (13.8 +/- 9.8 versus 14.9 +/- 5.0 micrograms.minute/mL) (P > .05), but Cmax decreased significantly (from 55.0 +/- 26.4 to 31.9 +/- 17.7 ng/mL) (P < .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[min·μg] / [ml],13.8,207020,DB00584,Enalapril
,10052059,AUC,"Renal failure had no significant effect on AUC for benazeprilat (13.8 +/- 9.8 versus 14.9 +/- 5.0 micrograms.minute/mL) (P > .05), but Cmax decreased significantly (from 55.0 +/- 26.4 to 31.9 +/- 17.7 ng/mL) (P < .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[min·μg] / [ml],14.9,207021,DB00584,Enalapril
,10052059,Cmax,"Renal failure had no significant effect on AUC for benazeprilat (13.8 +/- 9.8 versus 14.9 +/- 5.0 micrograms.minute/mL) (P > .05), but Cmax decreased significantly (from 55.0 +/- 26.4 to 31.9 +/- 17.7 ng/mL) (P < .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[ng] / [ml],55.0,207022,DB00584,Enalapril
,10052059,Cmax,"Renal failure had no significant effect on AUC for benazeprilat (13.8 +/- 9.8 versus 14.9 +/- 5.0 micrograms.minute/mL) (P > .05), but Cmax decreased significantly (from 55.0 +/- 26.4 to 31.9 +/- 17.7 ng/mL) (P < .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[ng] / [ml],31.9,207023,DB00584,Enalapril
,1312853,AUC (0.72 h),"4. Values of AUC (0.72 h) for enalaprilat were 419 +/- 97 and 450 +/- 87 ng ml-1 h in the presence and absence of captopril, respectively.",The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1312853/),[h·ng] / [ml],419,210329,DB00584,Enalapril
,1312853,AUC (0.72 h),"4. Values of AUC (0.72 h) for enalaprilat were 419 +/- 97 and 450 +/- 87 ng ml-1 h in the presence and absence of captopril, respectively.",The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1312853/),[h·ng] / [ml],450,210330,DB00584,Enalapril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [kcal·mol·mol],-7.6,212013,DB00584,Enalapril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [mol],-,212014,DB00584,Enalapril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [mol],8.8,212015,DB00584,Enalapril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [mol],8.0,212016,DB00584,Enalapril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),k,7.7,212017,DB00584,Enalapril
,3027821,bioavailability,"It is therefore administered as an inactive precursor, an énalaprilate ester which is hydrolysed in vivo with an ultimate bioavailability of 30-40 p. 100.",[Pharmacokinetics of enalapril]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3027821/),100·p,30-40,217974,DB00584,Enalapril
,2900730,CLR/fu.,"The CLR/fu.GFR, where fu is the unbound fraction, became 1.10 +/- 0.09 and 1.25 +/- 0.25, respectively.",Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900730/),,1.10,221673,DB00584,Enalapril
,2900730,CLR/fu.,"The CLR/fu.GFR, where fu is the unbound fraction, became 1.10 +/- 0.09 and 1.25 +/- 0.25, respectively.",Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900730/),,1.25,221674,DB00584,Enalapril
,2203579,Absorption,"Absorption of the active diacids is generally poor, and moderate (typically 30 to 70%) for the prodrugs.",Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,30 to 70,223514,DB00584,Enalapril
,2203579,bioavailability,The bioavailability of lisinopril is about 25%.,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,25,223515,DB00584,Enalapril
,2203579,Half-lives of accumulation,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),h,12,223516,DB00584,Enalapril
,2203579,protein binding,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,90,223517,DB00584,Enalapril
,8062492,area under the serum concentration-time curve (AUC),"When normalized to the oral 1 mg/m2 dose of enalapril maleate, the mean +/- SD area under the serum concentration-time curve (AUC) of enalaprilat, a pharmacologically active angiotensin-converting enzyme inhibitor, did not differ significantly between the pediatric group aged > 20 days and adult group (83.1 +/- 47.0 versus 64.6 +/- 17.8 ng.hr/ml per 1 mg/m2).",The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062492/),[h·ng] / [1·m2·mg·ml],83.1,227459,DB00584,Enalapril
,8062492,area under the serum concentration-time curve (AUC),"When normalized to the oral 1 mg/m2 dose of enalapril maleate, the mean +/- SD area under the serum concentration-time curve (AUC) of enalaprilat, a pharmacologically active angiotensin-converting enzyme inhibitor, did not differ significantly between the pediatric group aged > 20 days and adult group (83.1 +/- 47.0 versus 64.6 +/- 17.8 ng.hr/ml per 1 mg/m2).",The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062492/),[h·ng] / [1·m2·mg·ml],64.6,227460,DB00584,Enalapril
,8062492,AUC,"When normalized to the oral 0.1 mg/kg dose, the mean AUC was significantly (p < 0.05) smaller in this pediatric group than in the adult group (138.4 +/- 69.2 versus 245.7 +/- 61.8 ng.hr/ml per 0.1 mg/kg).",The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062492/),[h·ng] / [0·ml],138.4,227461,DB00584,Enalapril
,8062492,AUC,"When normalized to the oral 0.1 mg/kg dose, the mean AUC was significantly (p < 0.05) smaller in this pediatric group than in the adult group (138.4 +/- 69.2 versus 245.7 +/- 61.8 ng.hr/ml per 0.1 mg/kg).",The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062492/),[h·ng] / [0·ml],245.7,227462,DB00584,Enalapril
,8062492,AUC ratio,"The mean AUC ratio of enalaprilat to enalapril was significantly (p < 0.05) lower in the older pediatric subgroup (2.0 +/- 1.0) than in the adult group (3.4 +/- 1.6), whereas the mean ratios were comparable between the two subdivided pediatric groups.",The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062492/),,2.0,227463,DB00584,Enalapril
,8062492,AUC ratio,"The mean AUC ratio of enalaprilat to enalapril was significantly (p < 0.05) lower in the older pediatric subgroup (2.0 +/- 1.0) than in the adult group (3.4 +/- 1.6), whereas the mean ratios were comparable between the two subdivided pediatric groups.",The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062492/),,3.4,227464,DB00584,Enalapril
,2559191,J*max,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),,0.16,227785,DB00584,Enalapril
,2559191,Km,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),mM,0.08,227786,DB00584,Enalapril
,2559191,P*c,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),,2,227787,DB00584,Enalapril
,2559191,J*max,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),,0.032,227788,DB00584,Enalapril
,2559191,Km,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),mM,0.082,227789,DB00584,Enalapril
,2540786,urinary recovery,"3. Mean urinary recovery of lisinopril was 15 and 88% following oral and intravenous administration, respectively; absorption/bioavailability of lisinopril based on urinary recovery ratios was 16%, less than that found in normal subjects.",The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540786/),%,15,227959,DB00584,Enalapril
,2540786,urinary recovery,"3. Mean urinary recovery of lisinopril was 15 and 88% following oral and intravenous administration, respectively; absorption/bioavailability of lisinopril based on urinary recovery ratios was 16%, less than that found in normal subjects.",The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540786/),%,88,227960,DB00584,Enalapril
,2540786,absorption/bioavailability,"3. Mean urinary recovery of lisinopril was 15 and 88% following oral and intravenous administration, respectively; absorption/bioavailability of lisinopril based on urinary recovery ratios was 16%, less than that found in normal subjects.",The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540786/),%,16,227961,DB00584,Enalapril
,1665181,peak serum levels,"When given alone, peak serum levels of lisinopril (attained 6-8 hours post dose) were 44 ng/ml.",The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665181/),[ng] / [ml],44,238465,DB00584,Enalapril
,1665181,Urinary recovery,Urinary recovery was 17.6% of the dose.,The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665181/),,17,238466,DB00584,Enalapril
,1665181,peak serum concentration,"Dosing with hydrochlorothiazide alone resulted in a mean peak serum concentration of 53 ng/ml, 2-6 hours post dose.",The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665181/),[ng] / [ml],53,238467,DB00584,Enalapril
,2994938,elimination half-life,The elimination half-life for unchanged captopril is about 1.7 hours and is markedly increased in the presence of renal insufficiency.,Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2994938/),h,1.7,238933,DB00584,Enalapril
,2994938,tmax,"After the oral administration of enalapril, the tmax for enalapril is one hour, but for enalaprilat it is 4 hours.",Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2994938/),h,one,238934,DB00584,Enalapril
,2994938,tmax,"After the oral administration of enalapril, the tmax for enalapril is one hour, but for enalaprilat it is 4 hours.",Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2994938/),h,4,238935,DB00584,Enalapril
,2853897,urinary elimination,"3. After lisinopril alone, urinary elimination of unchanged lisinopril was 13% dose in 72 h, and after combined therapy was 17% dose.",A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2853897/),%,13,241403,DB00584,Enalapril
,2853897,urinary elimination,"3. After lisinopril alone, urinary elimination of unchanged lisinopril was 13% dose in 72 h, and after combined therapy was 17% dose.",A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2853897/),%,17,241404,DB00584,Enalapril
,15556550,ch,The chromatographic run time was approximately 3.5 min.,Simultaneous determination of enalapril and enalaprilat in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556550/),min,3.5,242494,DB00584,Enalapril
,15556550,run time,The chromatographic run time was approximately 3.5 min.,Simultaneous determination of enalapril and enalaprilat in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556550/),min,3.5,242495,DB00584,Enalapril
,21341376,total run time,"Chromatographic separation was carried out on a Hypurity C(18) column (50 mm × 4.6 mm, 5 µm) with an isocratic mobile phase and a total run time of 2.0 min only.","Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21341376/),min,2.0,242870,DB00584,Enalapril
,21341376,MRM,The MRM of ENP and ENPT is 377.10 → 234.20 and 349.20 → 206.10 respectively.,"Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21341376/),,377.10,242871,DB00584,Enalapril
,21341376,MRM,The MRM of ENP and ENPT is 377.10 → 234.20 and 349.20 → 206.10 respectively.,"Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21341376/),,234.20,242872,DB00584,Enalapril
,21341376,MRM,The MRM of ENP and ENPT is 377.10 → 234.20 and 349.20 → 206.10 respectively.,"Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21341376/),,349.20,242873,DB00584,Enalapril
,21341376,MRM,The MRM of ENP and ENPT is 377.10 → 234.20 and 349.20 → 206.10 respectively.,"Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21341376/),,206.10,242874,DB00584,Enalapril
,7564346,half-life (t 1/2),"Based on these preliminary data, the pharmacokinetic drug half-life (t 1/2) was estimated at 4.7 h and the EC50 was estimated at 41 ng/ml.",Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564346/),h,4.7,247622,DB00584,Enalapril
,7564346,EC50,"Based on these preliminary data, the pharmacokinetic drug half-life (t 1/2) was estimated at 4.7 h and the EC50 was estimated at 41 ng/ml.",Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564346/),[ng] / [ml],41,247623,DB00584,Enalapril
,25919042,excretion,Their excretion into the urine was measured from 0 h to 12 h.,Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25919042/),h,0,249695,DB00584,Enalapril
,25919042,excretion,Their excretion into the urine was measured from 0 h to 12 h.,Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25919042/),,12,249696,DB00584,Enalapril
,3034316,absorption,"Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%.",The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034316/),%,69,250335,DB00584,Enalapril
,3034316,absorption,"Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%.",The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034316/),%,55,250336,DB00584,Enalapril
,3034316,bioavailability,"Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%.",The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034316/),%,38,250337,DB00584,Enalapril
,3034316,first,"Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%.",The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034316/),%,10,250338,DB00584,Enalapril
,2410720,Apparent oral clearance,Apparent oral clearance after administration of 5 and 10 mg enalapril was lower in the congestive heart failure patients (0.6 +/- 0.2 and 0.7 +/- 0.4 L/min) than after 20 and 40 mg given to hypertensive patients (2.5 +/- 1.3 and 2.7 +/- 2.7 L/min).,Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410720/),[l] / [min],0.6,253088,DB00584,Enalapril
,2410720,Apparent oral clearance,Apparent oral clearance after administration of 5 and 10 mg enalapril was lower in the congestive heart failure patients (0.6 +/- 0.2 and 0.7 +/- 0.4 L/min) than after 20 and 40 mg given to hypertensive patients (2.5 +/- 1.3 and 2.7 +/- 2.7 L/min).,Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410720/),[l] / [min],0.7,253089,DB00584,Enalapril
,2410720,Apparent oral clearance,Apparent oral clearance after administration of 5 and 10 mg enalapril was lower in the congestive heart failure patients (0.6 +/- 0.2 and 0.7 +/- 0.4 L/min) than after 20 and 40 mg given to hypertensive patients (2.5 +/- 1.3 and 2.7 +/- 2.7 L/min).,Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410720/),[l] / [min],2.5,253090,DB00584,Enalapril
,2410720,Apparent oral clearance,Apparent oral clearance after administration of 5 and 10 mg enalapril was lower in the congestive heart failure patients (0.6 +/- 0.2 and 0.7 +/- 0.4 L/min) than after 20 and 40 mg given to hypertensive patients (2.5 +/- 1.3 and 2.7 +/- 2.7 L/min).,Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410720/),[l] / [min],2.7,253091,DB00584,Enalapril
,2410720,elimination,"The elimination of MK 422 was also slower in the congestive heart failure patients (7.8 +/- 5.0 and 6.8 +/- 2.5 h after 5 and 10 mg enalapril, respectively, vs. 4.6 +/- 2.0 and 5.3 +/- 1.1 h after 20 and 40 mg, respectively, in the hypertension group).",Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410720/),h,7.8,253092,DB00584,Enalapril
,2410720,elimination,"The elimination of MK 422 was also slower in the congestive heart failure patients (7.8 +/- 5.0 and 6.8 +/- 2.5 h after 5 and 10 mg enalapril, respectively, vs. 4.6 +/- 2.0 and 5.3 +/- 1.1 h after 20 and 40 mg, respectively, in the hypertension group).",Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410720/),h,6.8,253093,DB00584,Enalapril
,2410720,elimination,"The elimination of MK 422 was also slower in the congestive heart failure patients (7.8 +/- 5.0 and 6.8 +/- 2.5 h after 5 and 10 mg enalapril, respectively, vs. 4.6 +/- 2.0 and 5.3 +/- 1.1 h after 20 and 40 mg, respectively, in the hypertension group).",Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410720/),h,4.6,253094,DB00584,Enalapril
,2410720,elimination,"The elimination of MK 422 was also slower in the congestive heart failure patients (7.8 +/- 5.0 and 6.8 +/- 2.5 h after 5 and 10 mg enalapril, respectively, vs. 4.6 +/- 2.0 and 5.3 +/- 1.1 h after 20 and 40 mg, respectively, in the hypertension group).",Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410720/),h,5.3,253095,DB00584,Enalapril
,7898090,half-life,"We showed that single oral doses of cilazapril 4 mg, captopril 25 mg, or enalapril 10 mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacologic half-life of about 4 h for cilazapril.",Review of studies on the clinical pharmacodynamics of cilazapril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898090/),h,4,262739,DB00584,Enalapril
,7898090,apparent Ki dose,The dose representing 50% inhibition of ACE activity (apparent Ki dose) was about 0.6 mg 3 h after cilazapril administration.,Review of studies on the clinical pharmacodynamics of cilazapril. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898090/),mg,0.6,262740,DB00584,Enalapril
,22849770,t1/2,"Following single doses of ACT-178882, t1/2 and tmax varied from 18.7 to 24.7 h and from 3 to 5 h, respectively, and food had no significant effect.","Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22849770/),h,18.7 to 24.7,264352,DB00584,Enalapril
,22849770,tmax,"Following single doses of ACT-178882, t1/2 and tmax varied from 18.7 to 24.7 h and from 3 to 5 h, respectively, and food had no significant effect.","Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22849770/),h,3 to 5,264353,DB00584,Enalapril
,12746638,clearance,"ARF, although mild, decreased renal MET clearance (0.29 +/- 0.05 vs 1.01 +/- 0.31 ml/min/100 g, P<0.05) and increased plasma and renal tissue MET levels (x 2-4).",Mild acute renal failure potentiates metformin accumulation in the diabetic rat kidney without further impairment of renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746638/),[ml] / [100·g·min],0.29,264931,DB00584,Enalapril
,12746638,clearance,"ARF, although mild, decreased renal MET clearance (0.29 +/- 0.05 vs 1.01 +/- 0.31 ml/min/100 g, P<0.05) and increased plasma and renal tissue MET levels (x 2-4).",Mild acute renal failure potentiates metformin accumulation in the diabetic rat kidney without further impairment of renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746638/),[ml] / [100·g·min],1.01,264932,DB00584,Enalapril
,1322206,detection limit,The detection limit of enalapril and enalaprilat was 200 pg/mL in plasma and 2 ng/mL in urine.,Determination of enalapril and its active metabolite enalaprilat in plasma and urine by gas chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1322206/),[pg] / [ml],200,268787,DB00584,Enalapril
,1322206,detection limit,The detection limit of enalapril and enalaprilat was 200 pg/mL in plasma and 2 ng/mL in urine.,Determination of enalapril and its active metabolite enalaprilat in plasma and urine by gas chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1322206/),[ng] / [ml],2,268788,DB00584,Enalapril
